Affordable Access

Publisher Website

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine

Authors
Journal
Antimicrobial Agents and Chemotherapy
0066-4804
Publisher
American Society for Microbiology
Publication Date
Volume
50
Issue
10
Identifiers
DOI: 10.1128/aac.00372-06
Keywords
  • Antiviral Agents
Disciplines
  • Medicine

Abstract

Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2′-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2′-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.

There are no comments yet on this publication. Be the first to share your thoughts.